Meda AB (MEDA-A.ST): Dymista – Could be the Drug of Choice
5/4/2012 10:29:08 AM
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: The renowned Journal of Allergy and Clinical Immunology ((JACI;2012;129:1282–9) published an article on the clinical development program for Dymista (project code MP29-02), Meda’s novel intranasal therapy for allergic rhinitis (AR). The authors summarize the results of three clinical studies in a meta-analysis including 3,398 patients. They show that Dymista treats all symptoms more effectively than the currently recommended first-line therapies.
comments powered by